This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial
    • a randomized, double-blind trial involving 1873 patients with mild-to moderate, asymptomatic aortic stenosis
    • patients received either 40 mg of simvastatin plus 10 mg of ezetimibe or placebo daily
    • primary outcomes was a composite of major cardiovascular events
      • patients 45-85 years at baseline; a median follow-up of 52.2 months
      • simvastatin and ezetimibe did not reduce the composite primary endpoint
      • cancer occurred more frequently in the simvastatin-ezetimibe group (105 vs. 70, P = 0.01)
        • an apparent excess of about one half in the incidence of any new cancer was observed during mean follow-up of approximately 4 years among the 944 patients randomly assigned to ezetimibe plus simvastatin as compared with the 929 randomly assigned to placebo


  • following the results from SEAS an analysis of data from other ezetimibe trials was undertaken (2):
    • positive aspects of analysis
      • lack of cancer risk from analysis of 2 larger studies
      • SHARP
        • 9264 patients (mean follow-up 2.7 years)
        • patients at least 40 years of age at baseline Simvastatin 20mg/ezetimibe versus placebo
      • IMPROVE-IT
        • 11,353 patients (mean follow-up 1 year)
        • patients at least 50 years of age at baseline
        • simvastatin 40mg/ezetimibe versus simvastatin 40mg
      • no specific increase in a particular type of cancer in SEAS
    • the analysis suggests that:
      • data suggests a 'chance' finding - not a primary end point of any of the studies
      • data from two larger studies does not support findings from SEAS
    • however the data from the SHARP study and IMPROVE-IT study was over a lesser period of exposure to ezetimibe than in SEAS
      • need longer term data from SHARP and IMPROVE-IT to clarify the results further


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.